DXVX

DXVX · 180400

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$210.8M (₩290.9B)

Overview

DXVX is a South Korean biotech and healthcare company listed on KOSDAQ that provides genetic diagnostic testing, in-vitro diagnostic kits, and health-supplement products, while also developing novel drugs.

Hospitals, pharmaceutical companies, and research institutions use its genomic testing services, diagnostic reagents, and contract diagnostic manufacturing. Its business spans three distinct segments, medical diagnostics, healthcare products, and drug development, built partly through acquisitions of a health-supplement manufacturer and a drug-pipeline company.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$21.3M

▼ −13.5% YoY

Operating profit · FY2025

−US$17.6M

Loss widened

Net income · FY2025

−US$21.4M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$33.9M(₩46.7B)	US$24.6M(₩33.9B)	US$21.3M(₩29.4B)
Operating profit	−US$8.8M(−₩12.1B)	−US$15.6M(−₩21.6B)	−US$17.6M(−₩24.3B)
Net income	−US$20.2M(−₩27.8B)	−US$37.3M(−₩51.5B)	−US$21.4M(−₩29.6B)

Revenue

FY2023US$33.9M
FY2024US$24.6M
FY2025US$21.3M

Operating profit

FY2023−US$8.8M
FY2024−US$15.6M
FY2025−US$17.6M

Net income

FY2023−US$20.2M
FY2024−US$37.3M
FY2025−US$21.4M

Key ratios (FY2025)

ROE

-30.9%

Debt/Eq

61.7%

Op. margin

-82.8%

Net margin

-100.8%

Rev. YoY

▼ −13.5%

Why it matters

DXVX has established a China-based subsidiary, 北京디아이웨이스생물과기유한공사, to expand its health-supplement exports into the Chinese market.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?